Topics

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 21, Status: Authorised

12:45 EDT 11 Sep 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 21, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 21, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 21, Status: Authorised"

Quick Search

Relevant Topics

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...